Boston, MA, 03/13/2014 – Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA based molecular diagnostics has shared detailed plans about its product pipeline based on its proprietary technology in a news release.
MicroRNA Based Molecular Therapeutics
The company is developing microRNA based molecular diagnostics and therapeutics. Rosetta’s microRNA based therapeutics has three distinct projects called CMV therapeutic, Rimonim and Magneton projects.
Rosetta Genomics Ltd. (NASDAQ:ROSG) is already marketing four cancer diagnostics- The Cancer Origin Test, The Kidney Cancer Test, The Lung Cancer Test and The Mesothelioma Test. Now, it is seeking to advance several new diagnostic assays with the primary assay for the differential diagnosis of thyroid neoplasia. This test is tissue based microRNA diagnostics for the differential analysis of intermediate thyroid fine needle aspirate samples. Rosette expects to launch this assay by 2015.
MicroRNA Based Molecular Diagnostics
Apart from this, the company is also estimating several assays for other cancers and assays which include non invasive diagnosis of chronic kidney rejection. In this field, the company is working on developing urine or blood based microRNA biomarkers. The non invasive test can help in diagnosis at an earlier stage. Rosetta seeks to fully develop and launch this essay in 2017.
Rosetta Genomics Ltd. (NASDAQ:ROSG) is also working on the early identification and risk stratification of heart failure prone people. It is a blood based microRNA test. It has published two studies, one in the European Journal of Heart Failure in 2012 and the other one in the American Journal of Cardiology in 2013, in this case. It seeks to conduct more studies and subsequently launch a new assay in 2017.
Rosetta Genomics Ltd. (NASDAQ:ROSG) is evaluating another assay on the early diagnosis and differentiation of Alzheimer’s disease. It has collected serum samples of patients of the disease in contrast to serum samples healthy controls. It identified that many microRNAs in patients’ blood have a fixed direction when they made a comparison between their brain and brain cancer tissue. It plans to advance studies on this project this year.